Want to see HK:6978 full AI Analyst Report?
6978 Stock Chart & Stats
HK$2.68
-HK$0.01(-0.43%)
At close: 4:00 PM EST
HK$2.68
-HK$0.01(-0.43%)
Day’s Range― - ―
52-Week RangeHK$0.33 - HK$5.00
Previous CloseN/A
Volume50.00K
Average Volume (3M)73.92K
Market Cap
HK$250.09M
Enterprise ValueHK$718.18M
Total Cash (Recent Filing)HK$65.93M
Total Debt (Recent Filing)HK$402.12M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Mar 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding617,500,800
10 Day Avg. Volume85,900
30 Day Avg. Volume73,920
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)-103.70
Price to Sales (P/S)0.00
P/FCF Ratio-12.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Losses And Cash BurnThe improvement in both net losses and free cash flow during 2025 suggests some cost containment and better operating discipline. While the company remains unprofitable and cash consuming, a sustained reduction in losses could extend financial runway and support progress toward future commercialization.
Debt ReductionThe sharp reduction in total debt lowers the company’s absolute repayment burden and may reduce financing pressure compared with 2023. This provides some balance-sheet relief and could improve capital allocation flexibility, even though negative equity means overall solvency risk remains elevated.
Sizable Asset BaseA reported asset base of 603.2M gives the company a meaningful pool of resources relative to its current scale. Although assets do not eliminate funding or solvency concerns, their continued presence may provide operational support and potential flexibility as management pursues the biotech business.
Bears Say
No Reported RevenueThe absence of reported revenue over six years indicates that the business has not yet demonstrated commercial monetization. This limits internally generated funding, increases dependence on financing or other resources, and leaves future value tied primarily to successful development and eventual commercialization.
Negative Stockholders’ EquityThe shift into negative stockholders’ equity is a material structural weakness because liabilities exceed reported shareholder capital. It signals deteriorated financial resilience, constrains funding flexibility, and can make continued operations more dependent on external capital or balance-sheet restructuring.
Persistent Cash BurnConsistently negative operating and free cash flow shows that the business is not self-funding through its operations. Even with a lower burn rate in 2025, ongoing cash consumption requires continued access to external capital, increasing funding risk over the next several quarters.
Immunotech Biopharm Ltd News
6978 FAQ
What was Immunotech Biopharm Ltd’s price range in the past 12 months?
Immunotech Biopharm Ltd lowest stock price was HK$0.33 and its highest was HK$5.00 in the past 12 months.
What is Immunotech Biopharm Ltd’s market cap?
Immunotech Biopharm Ltd’s market cap is HK$250.09M.
When is Immunotech Biopharm Ltd’s upcoming earnings report date?
Immunotech Biopharm Ltd’s upcoming earnings report date is Mar 19, 2027 which is in 157 days.
How were Immunotech Biopharm Ltd’s earnings last quarter?
Immunotech Biopharm Ltd released its earnings results on Aug 21, 2026. The company reported -HK$0.129 earnings per share for the quarter.
Is Immunotech Biopharm Ltd overvalued?
According to Wall Street analysts Immunotech Biopharm Ltd’s price is currently Overvalued.
Does Immunotech Biopharm Ltd pay dividends?
Immunotech Biopharm Ltd does not currently pay dividends.
What is Immunotech Biopharm Ltd’s EPS estimate?
Immunotech Biopharm Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunotech Biopharm Ltd have?
Immunotech Biopharm Ltd has 617,500,800 shares outstanding.
What happened to Immunotech Biopharm Ltd’s price movement after its last earnings report?
Immunotech Biopharm Ltd reported an EPS of -HK$0.129 in its last earnings report. Following the earnings report the stock price went up 1.299%.
Which hedge fund is a major shareholder of Immunotech Biopharm Ltd?
Currently, no hedge funds are holding shares in HK:6978
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunotech Biopharm Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-91.85%
12-Months-Change
Fundamentals
Return on Equity
345.69%
Trailing 12-Months
Asset Growth
3.54%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immunotech Biopharm Ltd
Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in cellular immunotherapy. Its primary activities involve the investigation, development, and market introduction of T cell-based immunotherapy solutions for various cancers within the People's Republic of China. The company's flagship product, EAL, is a multi-target cellular immunotherapy currently undergoing Phase II clinical trials for the purpose of preventing liver cancer recurrence after surgery. Furthermore, Immunotech Biopharm is conducting both preclinical and clinical research on EAL for its potential use in treating lung cancer, glioma, gastric cancer, and colorectal cancer. Other pipeline assets include the 6B11-OCIK injection, which is in Phase I trials for ovarian cancer; the CAR-T-19 injection product, targeting B-cell acute lymphoblastic leukaemia; and a range of TCR-T cell products designed for solid tumor treatment. Established in 2006, the company's main office is located in Beijing, China.
Technical Analysis
Brii Biosciences Limited
―
JW (Cayman) Therapeutics Co. Ltd.
―
Mabpharm Limited
―
Transcenta Holding Limited
―
Wuhan YZY Biopharma Co., Ltd. Class H
―